Chemistry:MDMB-5'Br-BUTINACA
From HandWiki
Short description: Chemical compound
 | |
| Identifiers | |
|---|---|
| |
| PubChem CID | |
| Chemical and physical data | |
| Formula | C19H26BrN3O3 |
| Molar mass | 424.339 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
MDMB-5'Br-BUTINACA (5'-Br-MDMB-BUTINACA) is an indazole-3-carboxamide based synthetic cannabinoid receptor agonist that has been sold as a designer drug. It was first identified in Russia in August 2022. It is believed to be synthesized from the "half finished" synthesis precursor MDMB-5Br-INACA, which is shipped to the destination and then the final synthetic step is completed on arrival.[1][2][3]
See also
- 4F-MDMB-BINACA
- 6-Bromopravadoline
- ADB-PINACA
- ADB-5'F-BUTINACA
- ADB-5'Br-BUTINACA
- ADB-5'Br-PINACA
- ADSB-FUB-187
References
- ↑ Cumyl-PeGaClone and other recently encountered synthetic cannabinoid receptor agonists. A review of the evidence on their use and harms. Advisory Council on the Misuse of Drugs, 2022
- ↑ "Recent trends in the identification of psychoactive substances." (in Russian). Latest Trends in the Field of Identification of Psychoactive Substances 32. August 2022. doi:10.13140/RG.2.2.34906.62402. https://www.researchgate.net/publication/363137423.
- ↑ "In vitro cannabinoid activity profiling of generic ban-evading brominated synthetic cannabinoid receptor agonists and their analogs". Drug Testing and Analysis. October 2023. doi:10.1002/dta.3592. PMID 37903509.
 |  |
